{"doi":"10.1002/cncr.34915","title":"Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non–small cell lung cancer","abstract":"BACKGROUND: The PACIFIC trial established consolidative durvalumab after concurrent chemoradiation as standard-of-care in patients with stage III or unresectable non-small cell lung cancer (NSCLC). Black patients, however, comprised just 2% (n = 14) of randomized patients in this trial, warranting real-world evaluation of the PACIFIC regimen in these patients. METHODS: This single-institution, multi-site study included 105 patients with unresectable stage II/III NSCLC treated with concurrent chemoradiation followed by durvalumab between 2017 and 2021. Overall survival (OS), progression-free survival (PFS), and grade ≥3 pneumonitis-free survival (PNFS) were compared between Black and non-Black patients using Kaplan-Meier and Cox regression analyses. RESULTS: A total of 105 patients with a median follow-up of 22.8 months (interquartile range, 11.3-37.3 months) were identified for analysis, including 57 Black (54.3%) and 48 (45.7%) non-Black patients. The mean radiation prescription dose was higher among Black patients (61.5 ± 2.9 Gy vs. 60.5 ± 1.9 Gy; p = .031), but other treatment characteristics were balanced between groups. The median OS (not-reached vs. 39.7 months; p = .379) and PFS (31.6 months vs. 19.3 months; p = .332) were not statistically different between groups. Eight (14.0%) Black patients discontinued durvalumab due to toxicity compared to 13 (27.1%) non-Black patients (p = .096). The grade ≥3 pneumonitis rate was similar between Black and non-Black patients (12.3% vs. 12.5%; p = .973), and there was no significant difference in time to grade ≥3 PNFS (p = .904). Three (5.3%) Black patients and one (2.1%) non-Black patient developed grade 5 pneumonitis. CONCLUSIONS: The efficacy and tolerability of consolidative durvalumab after chemoradiation appears to be comparable between Black and non-Black patients.","journal":"Cancer","year":2023,"id":384397,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9071,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":421856,"name":"James Janopaul‐Naylor","orcid":"0000-0002-3612-4852","position":1,"is_corresponding":false},{"id":930579,"name":"Hamilton S. McGinnis","orcid":"0000-0002-3307-3703","position":2,"is_corresponding":false},{"id":250449,"name":"Aparna H. Kesarwala","orcid":"0000-0001-8297-9643","position":3,"is_corresponding":false},{"id":426285,"name":"Sibo Tian","orcid":"0000-0001-5018-4854","position":4,"is_corresponding":false},{"id":898467,"name":"William Stokes","orcid":"0000-0002-8684-0494","position":5,"is_corresponding":false},{"id":413773,"name":"Joseph W. Shelton","orcid":"0000-0003-0426-8197","position":6,"is_corresponding":false},{"id":314613,"name":"Conor Steuer","orcid":"0000-0001-6528-6319","position":7,"is_corresponding":false},{"id":254875,"name":"Jennifer W. Carlisle","orcid":"0000-0001-7085-4640","position":8,"is_corresponding":false},{"id":434077,"name":"Ticiana Leal","orcid":"0000-0002-3735-9063","position":9,"is_corresponding":false},{"id":79467,"name":"Suresh S. Ramalingam","orcid":"0000-0002-0757-3106","position":10,"is_corresponding":false},{"id":554291,"name":"Jeffrey D. Bradley","orcid":"0000-0001-9305-7396","position":11,"is_corresponding":false},{"id":267372,"name":"Kristin Higgins","orcid":"0000-0003-1496-9878","position":12,"is_corresponding":false},{"id":787983,"name":"Neal S. McCall","orcid":"0000-0001-7571-6984","position":0,"is_corresponding":true}],"reference_count":35,"raw_metadata":null,"created_at":"2026-07-19T01:17:33.041385Z","pmid":"37354070","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}